Skip to main content
Fig. 5 | Molecular Neurodegeneration

Fig. 5

From: Farnesyltransferase inhibitor LNK-754 attenuates axonal dystrophy and reduces amyloid pathology in mice

Fig. 5

LNK-754 improves learning and memory deficits in hAPP/PS1 mice. Female 6-month-old vehicle-treated wild-type mice, vehicle-treated hAPP/PS1 mice and LNK-754-treated hAPP/PS1 mice were trained in the Morris Water Maze (MWM) using a hidden platform and analyzed for the time to reach the platform in seven consecutive trials (A). # p < 0.01, LNK-754 treated hAPP/PS1 mice versus vehicle-treated hAPP/PS1 mice in the learning curve of the MWM, * p < 0.05 vehicle treated hAPP/PS1 mice versus wild-type controls in the learning curve of the MWM. Individual level data is shown for days 4 (*p = 0.040) (B) and 7 (*p = 0.030) (C). 24 hours after the last training day, each animal had a probe trial with the platform removed assessing the time spent in the hidden platform quadrant (*p = 0.016 between vehicle-treated wild-type and vehicle-treated hAPP/PS1, *p = 0.038 between vehicle-treated hAPP/PS1 and LNK-754 treated hAPP/PS1) (D) and the number of platform crossings (*p = 0.036 between vehicle-treated wild-type and vehicle-treated hAPP/PS1) (E). Platform 1 refers to the location of the original platform, platform 1 and 2 refers to the location of the original platform and a one-inch perimeter. Soluble (F) and insoluble (G) Aβ42 from brain homogenates of 6-month-old vehicle-treated wild-type mice, vehicle-treated hAPP/PS1 mice and LNK-754-treated hAPP/PS1 mice (vehicle-treated wild-type n = 12, vehicle-treated hAPP/PS1 n = 24, LNK-754-treated hAPP/PS1 mice n = 20). Dunnett’s multiple comparison test, unpaired t-test and 1-way ANOVA with Tukey’s post-hoc multiple comparisons test were performed

Back to article page